The data indicated PROVENGE treatment induced an antigen spread associated with an overall survival benefit in cases of advanced prostate cancer. The company also announced data from the PROCEED registry that indicated similar treatment patterns for urologists and oncologists in PROVENGE-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
The company plans to present the ProACT and IMPACT data via a podium presentation at the 2014 American Urological Association from May 16 to May 21 in Orlando. Dendreon will present the PROCEED data in a general poster session.
Must Read: Warren Buffett's 25 Favorite Stocks
The stock was up 8.41% to $2.32 at 10:49 a.m.
DNDN data by YCharts
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.